Developer docs
API playgroundTry for free, no card

Search company profiles

INCOG BioPharma

Full company profile

uuid0000ucj

Namestring
INCOG BioPharma
Legal namestring
INCOG BioPharma Services, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

INCOG BioPharma is a privately held contract development and manufacturing organization (CDMO) specializing in sterile injectable drug product fill/finish services for the global biopharmaceutical market. Founded in 2021 and headquartered in Fishers, Indiana, the company operates from a 21-acre, FDA-approved, Annex 1-compliant purpose-built campus featuring barrier isolation filling technology, OPTIMA MultiUse L6000 filling lines, AES Clean Technology modular cleanrooms, and capabilities across syringes (0.5–10mL), cartridges (1.5–5mL), and vials (2R–30R). Its integrated service portfolio spans formulation development, aseptic filling, analytical method development, device assembly and packaging for combination products (autoinjectors, pens, needle safety devices), and regulatory/compliance support for clinical through commercial phase programs.

The company targets market-leading biopharmaceutical companies for long-term strategic partnerships, engaging enterprise decision-makers via direct sales and major industry conferences such as BIO International, PDA Universe of Pre-filled Syringes, CPHI, INTERPHEX, DCAT, and the J.P. Morgan Healthcare Conference. Revenue is generated through project-based fee-for-service contracts covering clinical and commercial sterile injectable manufacturing. Following its first FDA commercial approval in 2024 with zero Form 483 observations, INCOG is executing a $200 million campus expansion announced in December 2025 that will add approximately 300,000 ft², scale annual fill capacity to 480 million units, and grow the workforce to nearly 1,000 employees by 2030.

Leadership is concentrated among co-founder Cory Lewis (CEO/President), co-founder Tedd Green (COO), and CFO Doug Dayhoff, supported by VPs of Quality, Technical Operations, Operations, and Business Development. The company is founder-owned with no disclosed institutional private equity backing, has raised approximately $86.6M in disclosed funding across 2020, 2022, and 2024 rounds, and is growing through a combination of operating cash flow, prior capital raises, and the $200M expansion investment. INCOG has been named one of Indiana's Best Places to Work for four consecutive years (2022–2025).

Short descriptiontext

INCOG BioPharma is a privately held sterile injectable CDMO providing end-to-end fill/finish, device assembly, and packaging services for clinical through commercial phase drug products. It serves global market-leading biopharmaceutical companies from its FDA-approved, Annex 1-compliant 21-acre campus in Fishers, Indiana.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersFishers, United States
HQ citystring
Fishers
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable manufacturing, fill finish CDMO services, aseptic filling services, biopharmaceutical contract manufacturing, injectable drug manufacturing
Industry1 code
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Development and Manufacturing (CDMO) Services for Sterile Injectables
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

INCOG operates as a Contract Development and Manufacturing Organization (CDMO) providing fee-for-service manufacturing to biopharmaceutical companies. Revenue is generated through project-based contracts for sterile injectable fill/finish services spanning clinical through commercial phases.

incogbiopharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

INCOG BioPharma is a fill/finish Contract Development and Manufacturing Organization (CDMO) providing end-to-end sterile injectable drug product manufacturing services from clinical through commercial phases. Its offering includes aseptic formulation and filling of syringes, cartridges, and vials using barrier isolation technology; automated device assembly and packaging for combination products; and support services such as QC testing, process scale-up, regulatory support, and material storage. Services are delivered from a 21-acre, FDA-approved and Annex 1-compliant campus in Fishers, Indiana.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Production capacity of 480 million units annually post-expansion
+2 more records
Product overview1 text field

INCOG BioPharma is a fill/finish Contract Development and Manufacturing Organization (CDMO) providing end-to-end solutions for clinical through commercial phase sterile injectable drug products for the global biopharmaceutical market. The company's core offering consists of three integrated service areas: (1) Formulation and Filling Services using barrier isolation technology for syringes, cartridges, and vials at clinical and commercial scale; (2) Device Assembly & Packaging for combination products including autoinjectors and pen injectors with full serialization and track-and-trace capabilities; and (3) Support Services including quality control testing, regulatory support, and material storage. The company operates from a 21-acre campus in Fishers, Indiana, featuring FDA-approved, Annex 1-compliant facilities with multiple OPTIMA filling lines.

Product and service4 records
1Formulation and Filling Services
CategoryAseptic Fill/Finish CDMO Services
Description

Aseptic fill/finish services for clinical through commercial scale manufacturing, handling syringes (0.5mL to 10mL), cartridges (1.5mL to 5mL), and vials (2R to 30R) using barrier isolation filling technology with time pressure or peristaltic pump mechanisms and non-destructive inline weight verification. Offered to biopharmaceutical companies requiring sterile injectable manufacturing.

2Device Assembly & Packaging
CategoryDevice Assembly and Packaging Services
Description

Automated assembly of complex combination products including autoinjectors (YpsoMate by Ypsomed, Molly by SHL Medical), pens, safety systems (BD UltraSafe Plus), and needle safety devices, with precision labeling, unit-dose serialization, and custom packaging configurations. Targeted at biopharmaceutical companies launching injectable combination products.

3Support Services
CategoryCDMO Support Services
Description

Comprehensive support including process design and scale-up, QC chemistry and microbiology testing, regulatory support and compliance, and material and finished product storage. Laboratory services include formulation and analytical development for clinical and commercial scale-up. Available to biopharmaceutical clients as part of INCOG's end-to-end CDMO offering.

4Sterile Injectable Drug Product CDMO Services
CategoryEnd-to-End CDMO Services
Description

End-to-end contract development and manufacturing organization services for sterile injectable drug products spanning clinical through commercial phases, integrating formulation, aseptic filling, analytical development, regulatory support, and final packaging. Offered to global biopharmaceutical companies.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-04-05
Description

AES Clean Technology equipped INCOG's state-of-the-art facility in Fishers with its modular cleanroom systems and high-performance HVAC technology to optimize environmental control. The partnership provided the flexibility and customization for growth, including the ability to quickly triple drug product manufacturing capacity via future capital investment projects.

Strategic tierCoreTypeTechnology or Integration
Description

OPTIMA Pharma provided the filling line equipment for INCOG's manufacturing facility. The OPTIMA MultiUse L6000 filling line drives up to 40M units of annual capacity for pre-filled syringes, cartridges, and vials and was cGMP qualified with its first media fill campaign.

Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Construction partner for the facility build-out, contributing to the rapid construction timeline that saw INCOG break ground and complete state-of-the-art build-out in under a year.

4Javan Engineering
Strategic tierSupportingTypeImplementation/ SI/ Consulting Partner
Description

Engineering partner contributing to the facility design and construction for INCOG's cleanroom production area.

incogbiopharma.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

INCOG BioPharma

Contract Development and Manufacturing (CDMO) Services for Sterile Injectablesincogbiopharma.com

INCOG BioPharma is a privately held sterile injectable CDMO providing end-to-end fill/finish, device assembly, and packaging services for clinical through commercial phase drug products. It serves global market-leading biopharmaceutical companies from its FDA-approved, Annex 1-compliant 21-acre campus in Fishers, Indiana.

What INCOG BioPharma does

INCOG BioPharma is a privately held contract development and manufacturing organization (CDMO) specializing in sterile injectable drug product fill/finish services for the global biopharmaceutical market. Founded in 2021 and headquartered in Fishers, Indiana, the company operates from a 21-acre, FDA-approved, Annex 1-compliant purpose-built campus featuring barrier isolation filling technology, OPTIMA MultiUse L6000 filling lines, AES Clean Technology modular cleanrooms, and capabilities across syringes (0.5–10mL), cartridges (1.5–5mL), and vials (2R–30R). Its integrated service portfolio spans formulation development, aseptic filling, analytical method development, device assembly and packaging for combination products (autoinjectors, pens, needle safety devices), and regulatory/compliance support for clinical through commercial phase programs.

The company targets market-leading biopharmaceutical companies for long-term strategic partnerships, engaging enterprise decision-makers via direct sales and major industry conferences such as BIO International, PDA Universe of Pre-filled Syringes, CPHI, INTERPHEX, DCAT, and the J.P. Morgan Healthcare Conference. Revenue is generated through project-based fee-for-service contracts covering clinical and commercial sterile injectable manufacturing. Following its first FDA commercial approval in 2024 with zero Form 483 observations, INCOG is executing a $200 million campus expansion announced in December 2025 that will add approximately 300,000 ft², scale annual fill capacity to 480 million units, and grow the workforce to nearly 1,000 employees by 2030.

Leadership is concentrated among co-founder Cory Lewis (CEO/President), co-founder Tedd Green (COO), and CFO Doug Dayhoff, supported by VPs of Quality, Technical Operations, Operations, and Business Development. The company is founder-owned with no disclosed institutional private equity backing, has raised approximately $86.6M in disclosed funding across 2020, 2022, and 2024 rounds, and is growing through a combination of operating cash flow, prior capital raises, and the $200M expansion investment. INCOG has been named one of Indiana's Best Places to Work for four consecutive years (2022–2025).

INCOG BioPharma firmographics

Firmographics
Name
INCOG BioPharma
Legal name
INCOG BioPharma Services, Inc.
Website
https://incogbiopharma.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
251–500 employees
Short description
INCOG BioPharma is a privately held sterile injectable CDMO providing end-to-end fill/finish, device assembly, and packaging services for clinical through commercial phase drug products. It serves global market-leading biopharmaceutical companies from its FDA-approved, Annex 1-compliant 21-acre campus in Fishers, Indiana.
Ownership category
akta.pro rank

INCOG BioPharma industry classification

Industry
Product category
Contract Development and Manufacturing (CDMO) Services for Sterile Injectables
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Sterile injectable manufacturing
  • Fill finish CDMO services
  • Aseptic filling services
  • Biopharmaceutical contract manufacturing
  • Injectable drug manufacturing

Where INCOG BioPharma is headquartered

Location

Headquarters

HQ city
Fishers
HQ country
United States
HQ region
North America

Offices1 record

Markets served

INCOG BioPharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Manufacturing Services: INCOG operates as a Contract Development and Manufacturing Organization (CDMO) providing fee-for-service manufacturing to biopharmaceutical companies. Revenue is generated through project-based contracts for sterile injectable fill/finish services spanning clinical through commercial phases.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

INCOG BioPharma product offering

Product offering

Core offering

INCOG BioPharma is a fill/finish Contract Development and Manufacturing Organization (CDMO) providing end-to-end sterile injectable drug product manufacturing services from clinical through commercial phases. Its offering includes aseptic formulation and filling of syringes, cartridges, and vials using barrier isolation technology; automated device assembly and packaging for combination products; and support services such as QC testing, process scale-up, regulatory support, and material storage. Services are delivered from a 21-acre, FDA-approved and Annex 1-compliant campus in Fishers, Indiana.

Product overview

INCOG BioPharma is a fill/finish Contract Development and Manufacturing Organization (CDMO) providing end-to-end solutions for clinical through commercial phase sterile injectable drug products for the global biopharmaceutical market. The company's core offering consists of three integrated service areas: (1) Formulation and Filling Services using barrier isolation technology for syringes, cartridges, and vials at clinical and commercial scale; (2) Device Assembly & Packaging for combination products including autoinjectors and pen injectors with full serialization and track-and-trace capabilities; and (3) Support Services including quality control testing, regulatory support, and material storage. The company operates from a 21-acre campus in Fishers, Indiana, featuring FDA-approved, Annex 1-compliant facilities with multiple OPTIMA filling lines.

Differentiator

Problem solved

Functional benefit

Products and services

  • Formulation and Filling Services Aseptic fill/finish services for clinical through commercial scale manufacturing, handling syringes (0.5mL to 10mL), cartridges (1.5mL to 5mL), and vials (2R to 30R) using barrier isolation filling technology with time pressure or peristaltic pump mechanisms and non-destructive inline weight verification. Offered to biopharmaceutical companies requiring sterile injectable manufacturing.
  • Device Assembly & Packaging Automated assembly of complex combination products including autoinjectors (YpsoMate by Ypsomed, Molly by SHL Medical), pens, safety systems (BD UltraSafe Plus), and needle safety devices, with precision labeling, unit-dose serialization, and custom packaging configurations. Targeted at biopharmaceutical companies launching injectable combination products.
  • Support Services Comprehensive support including process design and scale-up, QC chemistry and microbiology testing, regulatory support and compliance, and material and finished product storage. Laboratory services include formulation and analytical development for clinical and commercial scale-up. Available to biopharmaceutical clients as part of INCOG's end-to-end CDMO offering.
  • Sterile Injectable Drug Product CDMO Services End-to-end contract development and manufacturing organization services for sterile injectable drug products spanning clinical through commercial phases, integrating formulation, aseptic filling, analytical development, regulatory support, and final packaging. Offered to global biopharmaceutical companies.

Quantifiable outcome

  • Production capacity of 480 million units annually post-expansion
  • +2 more outcomes

Companies that use INCOG BioPharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

INCOG BioPharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

INCOG BioPharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • AES Clean TechnologycoreTechnology or Integration · 5 April 2022AES Clean Technology equipped INCOG's state-of-the-art facility in Fishers with its modular cleanroom systems and high-performance HVAC technology to optimize environmental control. The partnership provided the flexibility and customization for growth, including the ability to quickly triple drug product manufacturing capacity via future capital investment projects.
  • OPTIMA PharmacoreTechnology or IntegrationOPTIMA Pharma provided the filling line equipment for INCOG's manufacturing facility. The OPTIMA MultiUse L6000 filling line drives up to 40M units of annual capacity for pre-filled syringes, cartridges, and vials and was cGMP qualified with its first media fill campaign.
  • Shiel SextonsupportingImplementation/ SI/ Consulting PartnerConstruction partner for the facility build-out, contributing to the rapid construction timeline that saw INCOG break ground and complete state-of-the-art build-out in under a year.
  • Javan EngineeringsupportingImplementation/ SI/ Consulting PartnerEngineering partner contributing to the facility design and construction for INCOG's cleanroom production area.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

INCOG BioPharma competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

INCOG BioPharma social profiles

Digital presence

INCOG BioPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

INCOG BioPharma leadership team

Management profile

Number of profiles

Profiles7 records

INCOG BioPharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

INCOG BioPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INCOG BioPharma

What does INCOG BioPharma do?

INCOG BioPharma is a fill/finish Contract Development and Manufacturing Organization (CDMO) providing end-to-end sterile injectable drug product manufacturing services from clinical through commercial phases. Its offering includes aseptic formulation and filling of syringes, cartridges, and vials using barrier isolation technology; automated device assembly and packaging for combination products; and support services such as QC testing, process scale-up, regulatory support, and material storage. Services are delivered from a 21-acre, FDA-approved and Annex 1-compliant campus in Fishers, Indiana.

Is INCOG BioPharma a public or private company?

INCOG BioPharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was INCOG BioPharma founded?

INCOG BioPharma was founded in 2021. It employs 251 to 500 people.

Where is INCOG BioPharma based?

INCOG BioPharma is headquartered in Fishers, United States, in the North America region.

How does INCOG BioPharma make money?

One revenue line is on record: contract Manufacturing Services.

Does INCOG BioPharma have an API?

No public API is recorded for INCOG BioPharma.

What industry is INCOG BioPharma in?

INCOG BioPharma's product category is Contract Development and Manufacturing (CDMO) Services for Sterile Injectables. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Inside Indiana BusinessFrom quiet powerhouse to talent magnet: How Indiana can compete with coastal life sciences hubs – Inside INdiana BusinessThe author argues that Indiana has the foundational ingredients—a collaborative culture, existing anchor institutions, and talent—to build a life sciences ecosystem that can rival coastal hubs, but must address two key weaknesses: slower business tempo and limited access to early-stage capital. The article cites Fishers as a model of successful cluster development, where companies including INCOG BioPharma, Genezen, 1Elevan Biopharmaceuticals, Telix Pharmaceuticals, and Quantigen Biosciences have established operations, demonstrating that targeted local strategy can attract and retain life sciences employers. The author proposes that Indiana allocate a portion of its $50 billion state employee pension funds to invest in Indiana life sciences companies and specialized funds as a disciplined approach to aligning long-term capital with economic interests.DcatvciCDMOs Roll Out Expansions for Parenteral DrugsMultiple Contract Development and Manufacturing Organizations (CDMOs) are expanding production capacity for injectable drugs in response to projected strong growth in the global injectables market driven by biologics and specialty therapeutics demand. Recent expansions include Vetter's EUR 480-million facility in Germany, Thermo Fisher Scientific's acquisition of Sanofi's sterile manufacturing site in New Jersey, Incog BioPharma Services' $200-million investment in Indiana, and Lonza's CHF 500-million facility in Switzerland, among others. The article also notes macro challenges facing the industry, including tariff/trade uncertainties, policy push for US-based manufacturing, and potential margin pressure from US drug pricing reforms.Business Facilities Magazine$21M Venture Fund, Three Expansions Fuel Indiana Life Sciences$21M Venture Fund, Three Expansions Fuel Indiana Life SciencesIndiana launched Crossroads Health Ventures (CHV), a new early-stage venture fund with over $21 million in commitments from partners including Lilly Ventures, Corteva, Elanco, and state entities, to accelerate life sciences startups. The fund will begin deploying capital in early 2026 as Indiana's life sciences sector expands, with three company projects expected to create more than 1,300 high-wage jobs across the state. INCOG BioPharma Services is investing $200 million to double its workforce to nearly 1,000 employees at its Fishers campus, while West Pharmaceutical Services is establishing a new Greenfield operation creating up to 300 jobs, and Autocam Medical is expanding in Warsaw, adding 300 positions.ReadthereporterIndiana’s life sciences sector growing with more than 1,300 new high‑wage jobs across the stateIndiana Governor Mike Braun announced three life sciences sector expansions on January 14 that will create more than 1,300 new high-wage jobs across the state. INCOG BioPharma Services is investing $200 million to double its Fishers workforce to nearly 1,000 employees by 2030, while West Pharmaceutical Services is establishing a new Greenfield manufacturing operation with up to 300 jobs, and Autocam Medical is adding 300 positions at its Warsaw facility. The announcements underscore Indiana's positioning as a national hub for advanced manufacturing, medical device production, and biopharmaceutical innovation.WBIWGov. Braun accelerates life sciences leadership with more than 1,300 new high wage jobs across the stateIndiana Gov. Mike Braun announced three major life sciences industry expansions that will create more than 1,300 new high-wage jobs across the state in Fishers, Greenfield, and Warsaw. INCOG BioPharma Services is investing $200 million to double its Fishers workforce to nearly 1,000 employees by 2030 and expand its injectable drug manufacturing capacity to 480 million units annually. These expansions further cement Indiana's position as a national leader in biopharmaceutical and medical device manufacturing, with jobs paying 125–159% above county average wages.Pharmaceutical TechnologyINCOG reveals $200m injectable drug expansion in IndianaINCOG BioPharma Services has announced a $200 million expansion of its injectable drug manufacturing at its Fishers facility in Indiana, set to begin in early 2026. This expansion will add approximately 300,000 square feet and aims to establish the site as a key global manufacturing center for injectable biopharmaceuticals, potentially creating around 1,000 jobs by 2030.YahooINCOG reveals $200m injectable drug expansion in IndianaCDMO INCOG BioPharma Services has announced a $200 million expansion of its injectable drug manufacturing facility in Fishers, Indiana, with construction set to begin in early 2026. The expansion will add approximately 300,000 ft² to the 21-acre campus, increasing production capacity to 480 million units annually and growing the workforce to around 1,000 employees by 2030. The investment, supported by Indiana state incentives, positions the Fishers site as a global manufacturing centre for sterile fill/finish of injectable biopharmaceutical products.Bioprocess Online for bioanalyticsINCOG Biopharma Services Announces Significant 2025 Expansion Efforts, Celebrates 2024 MilestonesINCOG BioPharma Services announced 2025 expansion plans, including an 113,000-square-foot facility in Fishers, IN, and a new Optima filling line adding 100 million syringe and cartridge units. The company will hire to reach over 350 employees by summer, building on 2024 milestones like a successful FDA inspection and 20 customer audits.SecSEC FORM DINCOG BioPharma Services, Inc. filed a Form D with the SEC for an exempt offering of equity securities under Rule 506(b), with total sales amounting to $42,864,002 USD. The filing indicates that one investor has already participated in the offering, which is located in Fishers, Indiana. The company disclosed no sales commissions or finder's fees associated with this transaction.SecSEC FORM DINCOG BioPharma Services, Inc. filed a Form D with the Securities and Exchange Commission for an exempt offering of equity securities under Rule 506(b). The filing indicates a total offering amount of $42,864,002, with sales commencing on May 14, 2024. The company is based in Fishers, Indiana, and incorporated in Delaware.